The first study on deuterium-depleted water (DDW) concluded that a higher D/H ratio inside cells can trigger cell division.

In parallel, MerryLife is exploring the potential relevance of TML-6 in Parkinson's disease, where similar pathological mechanisms contribute to disease progression. The company will present ...

Abstract: The time-varying phase-switched screen (PSS) has demonstrated a significant potential for modulating radar target features, due to its exceptional capabilities in the harmonic generation and ...

Abstract: Triple-phase-shift (TPS) modulation endows dual-active-bridge (DAB) DC-DC converters with three independent degrees of freedom, enabling simultaneous control of power flow, device stress, ...

The Phase 1 clinical trial, STRIKE-001 (NCT07103018), is a multi-center, open-label dose escalation of KTX-2001 monotherapy (Part A) and in combination with darolutamide, an oral, nonsteroidal ...

Chowning is a composer, musician and professor that had a seismic impact on both the development of music technology and the ...

OVATION 3 is IMUNON’s pivotal Phase 3 study of IMMN-001, an IL-12 gene-mediated immunotherapy, in women with advanced stage epithelial ovarian cancer. The study is supported with unprecedented overall ...

LCGC International salutes Jack Henion and Bob W.J. Pirok, winners of the 19th annual LCGC Lifetime Achievement and Emerging ...

Dewpoint Therapeutics, Inc., a clinical-stage biotechnology company pioneering condensate-modulating therapeutics, today announced that the first patient has been dosed in a Phase 1a/2a clinical trial ...

The FDA approved a fixed-dose combination of carbachol and brimonidine tartrate for presbyopia, offering a noninvasive ...

The FDA endorsed a ≥2-point reduction on a visual analogue scale for pain as a clinically meaningful endpoint for urcosimod in NCP. NCP is a chronic ocular pain syndrome with no FDA-approved therapies ...